Zhengye Biotechnology Holding (ZYBT) Notes Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Notes Payables data on file, last reported at $9.2 million in Q4 2025.

• Notes Payables for Q4 2025 came in at $9.2 million, down 11.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.2 million (down 11.43% YoY), and the FY2025 annual result was $9.3 million, down 8.73% from the prior year.
• Notes Payables declined to $9.2 million in Q4 2025 per ZYBT's latest filing, from $11.3 million in the prior quarter.
• Over five years, Notes Payables peaked at $11.3 million in Q2 2025 and troughed at $9.2 million in Q4 2025.
• A 3-year average of $10.5 million and a median of $10.7 million in 2023 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2024 and 2025: Notes Payables decreased 6.56% in 2024, then fell 11.43% in 2025.
• A 3-year view of Notes Payables shows it stood at $11.1 million in 2023, then fell by 6.56% to $10.4 million in 2024, then declined by 11.43% to $9.2 million in 2025.
• Business Quant data shows ZYBT's Notes Payables at $9.2 million in Q4 2025, $11.3 million in Q2 2025, and $10.4 million in Q4 2024.